SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
SANTA CLARA, Calif., May 19, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces continued growth in 2017 with dramatic first quarter results.
In Q1 17 revenue reached NT$493 million, a 34% YOY (year-over-year) growth. Gross margin reached 49.3% with EPS (earnings per share) of NT$0.13. With the strong demand for Oncology and Immunology therapy, the company anticipates sustained revenue growth and increased profitability through 2017.
To achieve this growth CrownBio leveraged its existing platforms of patient-derived xenograft (PDX) and cell line derived xenograft pharmacology models, and expanded immuno-oncology translatable models while broadening the portfolio offering to inflammatory disease. This extensive portfolio supports the therapeutic continuum of Oncology, Cardiovascular, Metabolic, and Inflammatory disease research.
“The double and triple digit growth regionally, proves CrownBio’s global reach and strong local presence is servicing our client base with sound scientific offerings,” said Laurie Heilmann, SVP of Global Strategy, Business Development and Marketing, “Our Immuno-Oncology, Cardiovascular, and Metabolic translatable models, along with strong performance in Europe, US, and the Western APAC region were significant contributors to the growth.”
Continued diversity across their service offerings, while remaining client centric, has enabled CrownBio to secure confidence by demonstrating growth in 75% of the top tier pharma companies. “CrownBio brings clarity to drug discovery with end to end solutions that help recognize the next clinical candidate sooner,” said Dr. Jean-Pierre Wery, CEO. “We will further advance preclinical and clinical research through accelerating development of technologies, including biomarker discovery and precision diagnosis that are needed to bring the right molecule to market.”
For more information on CrownBio’s commitment to furthering the field of oncology and metabolic disease drug discovery, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
